Generative Active Learning for the Search of Small-molecule Protein Binders
Authors:
Maksym Korablyov,
Cheng-Hao Liu,
Moksh Jain,
Almer M. van der Sloot,
Eric Jolicoeur,
Edward Ruediger,
Andrei Cristian Nica,
Emmanuel Bengio,
Kostiantyn Lapchevskyi,
Daniel St-Cyr,
Doris Alexandra Schuetz,
Victor Ion Butoi,
Jarrid Rector-Brooks,
Simon Blackburn,
Leo Feng,
Hadi Nekoei,
SaiKrishna Gottipati,
Priyesh Vijayan,
Prateek Gupta,
Ladislav Rampášek,
Sasikanth Avancha,
Pierre-Luc Bacon,
William L. Hamilton,
Brooks Paige,
Sanchit Misra
, et al. (9 additional authors not shown)
Abstract:
Despite substantial progress in machine learning for scientific discovery in recent years, truly de novo design of small molecules which exhibit a property of interest remains a significant challenge. We introduce LambdaZero, a generative active learning approach to search for synthesizable molecules. Powered by deep reinforcement learning, LambdaZero learns to search over the vast space of molecu…
▽ More
Despite substantial progress in machine learning for scientific discovery in recent years, truly de novo design of small molecules which exhibit a property of interest remains a significant challenge. We introduce LambdaZero, a generative active learning approach to search for synthesizable molecules. Powered by deep reinforcement learning, LambdaZero learns to search over the vast space of molecules to discover candidates with a desired property. We apply LambdaZero with molecular docking to design novel small molecules that inhibit the enzyme soluble Epoxide Hydrolase 2 (sEH), while enforcing constraints on synthesizability and drug-likeliness. LambdaZero provides an exponential speedup in terms of the number of calls to the expensive molecular docking oracle, and LambdaZero de novo designed molecules reach docking scores that would otherwise require the virtual screening of a hundred billion molecules. Importantly, LambdaZero discovers novel scaffolds of synthesizable, drug-like inhibitors for sEH. In in vitro experimental validation, a series of ligands from a generated quinazoline-based scaffold were synthesized, and the lead inhibitor N-(4,6-di(pyrrolidin-1-yl)quinazolin-2-yl)-N-methylbenzamide (UM0152893) displayed sub-micromolar enzyme inhibition of sEH.
△ Less
Submitted 2 May, 2024;
originally announced May 2024.
RECOVER: sequential model optimization platform for combination drug repurposing identifies novel synergistic compounds in vitro
Authors:
Paul Bertin,
Jarrid Rector-Brooks,
Deepak Sharma,
Thomas Gaudelet,
Andrew Anighoro,
Torsten Gross,
Francisco Martinez-Pena,
Eileen L. Tang,
Suraj M S,
Cristian Regep,
Jeremy Hayter,
Maksym Korablyov,
Nicholas Valiante,
Almer van der Sloot,
Mike Tyers,
Charles Roberts,
Michael M. Bronstein,
Luke L. Lairson,
Jake P. Taylor-King,
Yoshua Bengio
Abstract:
For large libraries of small molecules, exhaustive combinatorial chemical screens become infeasible to perform when considering a range of disease models, assay conditions, and dose ranges. Deep learning models have achieved state of the art results in silico for the prediction of synergy scores. However, databases of drug combinations are biased towards synergistic agents and these results do not…
▽ More
For large libraries of small molecules, exhaustive combinatorial chemical screens become infeasible to perform when considering a range of disease models, assay conditions, and dose ranges. Deep learning models have achieved state of the art results in silico for the prediction of synergy scores. However, databases of drug combinations are biased towards synergistic agents and these results do not necessarily generalise out of distribution. We employ a sequential model optimization search utilising a deep learning model to quickly discover synergistic drug combinations active against a cancer cell line, requiring substantially less screening than an exhaustive evaluation. Our small scale wet lab experiments only account for evaluation of ~5% of the total search space. After only 3 rounds of ML-guided in vitro experimentation (including a calibration round), we find that the set of drug pairs queried is enriched for highly synergistic combinations; two additional rounds of ML-guided experiments were performed to ensure reproducibility of trends. Remarkably, we rediscover drug combinations later confirmed to be under study within clinical trials. Moreover, we find that drug embeddings generated using only structural information begin to reflect mechanisms of action. Prior in silico benchmarking suggests we can enrich search queries by a factor of ~5-10x for highly synergistic drug combinations by using sequential rounds of evaluation when compared to random selection, or by a factor of >3x when using a pretrained model selecting all drug combinations at a single time point.
△ Less
Submitted 2 March, 2023; v1 submitted 6 February, 2022;
originally announced February 2022.